AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33035700 — intervention group
Group type: EXPERIMENTAL
Intervention: IND/GLY/MF 150/50/160 μg
Number of subjects: 36
Study 34302941 — intervention group
Group type: EXPERIMENTAL
Intervention: High repetition-load resistance training (n = 30)
Number of subjects: 60
Study 34302941 — intervention group
Group type: COMPARATOR
Intervention: Low repetition-load resistance training (n = 28)
Number of subjects: 60
Study 34302941 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 60
Study 32328662 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing adjuvant temozolomide (up to 12 cycles)
Number of subjects: 159
Study 32328662 — intervention group
Group type: COMPARATOR
Intervention: Stopping adjuvant temozolomide (control arm)
Number of subjects: 159
Study 35016561 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Recumbent Stepping (TBRS)
Number of subjects: 19
Study 35016561 — intervention group
Group type: COMPARATOR
Intervention: Treadmill Walking (TM)
Number of subjects: 19
Study 33787831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 4744
Study 33787831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 32086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysosmia group (n=64)
Number of subjects: 105
Study 32086921 — intervention group
Group type: COMPARATOR
Intervention: Non-dysosmia group (n=41)
Number of subjects: 105
Study 32086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with olfactory dysfunction
Number of subjects: 105
Study 32086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients with olfactory dysfunction
Number of subjects: 105
Study 32086921 — intervention group
Group type: EXPERIMENTAL
Intervention: SCL-90 score of chronic sinusitis patients with olfactory dysfunction (n=64)
Number of subjects: 105
Study 32086921 — intervention group
Group type: COMPARATOR
Intervention: SCL-90 score of chronic sinusitis patients without olfactory dysfunction (n=41)
Number of subjects: 105
Study 32208999 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid plus standard verbal counseling
Number of subjects: 31
Study 32208999 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal counseling alone
Number of subjects: 31
Study 32208999 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 31
Study 32208999 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal counseling duration
Number of subjects: 31
Study 33606892 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (FAV)
Number of subjects: 0
Study 33606892 — intervention group
Group type: COMPARATOR
Intervention: Internal standard (Lamivudine)
Number of subjects: 0
Study 35575587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole (Ribociclib 600 mg once daily for 3 weeks on/1 week off, Letrozole 2.5 mg continuously)
Number of subjects: 339
Study 35575587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 339
Study 33507500 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 246
Study 33507500 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 246
Study 35224090 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Movement (CPM)
Number of subjects: 60
Study 35224090 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy alone (non-CPM group)
Number of subjects: 60
Study 33038506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health (CVH) mHealth intervention, addressing behaviors related to CVD risk.
Number of subjects: 302
Study 33038506 — intervention group
Group type: COMPARATOR
Intervention: Whole Health (WH) mHealth intervention, addressing behaviors unrelated to CVD.
Number of subjects: 302
Study 36151855 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine with central monitoring of QIDS‐J and MADRS ratings
Number of subjects: 0
Study 36151855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33777184 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI)
Number of subjects: 13
Study 33777184 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 13
Study 32199755 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive marker-based follow-up (UroVysion, NMP22, urine cytology, and ultrasound)
Number of subjects: 185
Study 32199755 — intervention group
Group type: COMPARATOR
Intervention: Usual care with cystoscopy
Number of subjects: 185
Study 35618629 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy plus radiotherapy with pembrolizumab (Group A)
Number of subjects: 190
Study 35618629 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy plus radiotherapy with pembrolizumab plus olaparib (Group B)
Number of subjects: 190
Study 35618629 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab monotherapy (Group C)
Number of subjects: 190
Study 33413304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified app
Number of subjects: 58
Study 33413304 — intervention group
Group type: COMPARATOR
Intervention: Simple app
Number of subjects: 58
Study 35264432 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 584
Study 35264432 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg + MTX
Number of subjects: 584
Study 35264432 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 584
Study 35264432 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg or Baricitinib 4 mg + MTX
Number of subjects: 584
Study 33638221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (OVT)
Number of subjects: 0
Study 33638221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 33638221 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study 33424089 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 1gr/8hours IV acetaminophen and 50mg/6hours IM pethidine
Number of subjects: 259
Study 33424089 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1gr/8hours IV acetaminophen and 40mg/12hours IV parecoxib
Number of subjects: 259
Study 33424089 — intervention group
Group type: COMPARATOR
Intervention: Group C: 1gr/8hours IV acetaminophen monotherapy
Number of subjects: 259
Study 36128685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced follow-up by stoma therapists (STs) with regular consultations after discharge.
Number of subjects: 0
Study 36128685 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up without enhanced management.
Number of subjects: 0
Study 33940389 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat (up to 300 mg BID)
Number of subjects: 18
Study 33940389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33940389 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (Soticlestat in Part B)
Number of subjects: 18
Study 35119781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 25 mmHg (LBNP25)
Number of subjects: 9
Study 32895116 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with a telemonitoring system
Number of subjects: 60
Study 32895116 — intervention group
Group type: COMPARATOR
Intervention: CPAP with usual care
Number of subjects: 60
Study 34634436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated chemoradiation (5 × 3 gray boost + CRT)
Number of subjects: 115
Study 34634436 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiation (control group)
Number of subjects: 115
Study 33091173 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2i (Dapagliflozin)
Number of subjects: 0
Study 33091173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34050531 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery of an oral health intervention
Number of subjects: 448
Study 34050531 — intervention group
Group type: COMPARATOR
Intervention: Delayed delivery of an oral health intervention
Number of subjects: 448
Study 32468652 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy
Number of subjects: 0
Study 36442199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 0
Study 36442199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Number of subjects: 0
Study 36442199 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 0
Study 36442199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 34406395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 26
Study 34406395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 35390512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 13523
Study 35390512 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 13523
Study 33743631 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus stage 1
Number of subjects: 150
Study 33743631 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus stage 2
Number of subjects: 150
Study 33743631 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus stage 3
Number of subjects: 150
Study 32991233 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0
Study 32991233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35279655 — intervention group
Group type: EXPERIMENTAL
Intervention: HD + MCO
Number of subjects: 14
Study 35279655 — intervention group
Group type: COMPARATOR
Intervention: mixed-dilution olHDF
Number of subjects: 14
Study 32387569 — intervention group
Group type: EXPERIMENTAL
Intervention: Anophthalmic side
Number of subjects: 87
Study 34719355 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐puncture Type‐1 arthrocentesis (SPA)
Number of subjects: 50
Study 34719355 — intervention group
Group type: COMPARATOR
Intervention: Conventional double‐puncture arthrocentesis (DPA)
Number of subjects: 50
Study 34719355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SPA and DPA)
Number of subjects: 50
Study 36318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute care (PAC) utilization
Number of subjects: 718737
Study 36318635 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC cost
Number of subjects: 718737
Study 36318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital readmissions
Number of subjects: 718737
Study 36318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive in the community
Number of subjects: 718737
Study 36318635 — intervention group
Group type: EXPERIMENTAL
Intervention: 180-day Medicare costs
Number of subjects: 718737
Study 36318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 718737
Study 33230029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated and monitored ART (NIMART)
Number of subjects: 1760
Study 33230029 — intervention group
Group type: COMPARATOR
Intervention: Clinician-initiated and monitored ART
Number of subjects: 1760
Study 32773608 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 785
Study 32773608 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 785
Study 33558417 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital personality change intervention using the smartphone application PEACH for 3 months
Number of subjects: 1523
Study 33558417 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (1 month delay before receiving the intervention)
Number of subjects: 1523
Study 33558417 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital personality change intervention
Number of subjects: 1523
Study 35120326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 682
Study 35120326 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 682
Study 33960263 — intervention group
Group type: EXPERIMENTAL
Intervention: S-STOP program (intervention)
Number of subjects: 303
Study 33960263 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed implementation)
Number of subjects: 303
Study 32795986 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook recruitment method
Number of subjects: 1417
Study 32795986 — intervention group
Group type: EXPERIMENTAL
Intervention: TV advertisements recruitment method
Number of subjects: 1417
Study 32795986 — intervention group
Group type: EXPERIMENTAL
Intervention: Public bus interior card advertising recruitment method
Number of subjects: 1417
Study 35248042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild CS (2 mm < DH decrease ≤ 4 mm)
Number of subjects: 242
Study 35248042 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CS (DH decrease > 4 mm)
Number of subjects: 242
Study 35248042 — intervention group
Group type: COMPARATOR
Intervention: No CS (DH decrease ≤ 2 mm)
Number of subjects: 242
Study 35248042 — intervention group
Group type: EXPERIMENTAL
Intervention: CS related risk factors
Number of subjects: 242
Study 33231489 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 301 210 mg every 4 weeks
Number of subjects: 343
Study 33231489 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 301 420 mg every 2 weeks
Number of subjects: 343
Study 33231489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 34563992 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with cisplatin
Number of subjects: 455
Study 34563992 — intervention group
Group type: COMPARATOR
Intervention: TACE with epirubicin
Number of subjects: 455
Study 36018625 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth program with online education videos and video consultations
Number of subjects: 280
Study 36018625 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 280
Study 32106721 — intervention group
Group type: EXPERIMENTAL
Intervention: n-BiPAP
Number of subjects: 149
Study 32106721 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 149
Study 32882355 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' ratings of patient's physical distress at EOL
Number of subjects: 168
Study 32882355 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' ratings of patient's psychological distress at EOL
Number of subjects: 168
Study 35940353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone group (10 mg extended-release oxycodone hydrochloride)
Number of subjects: 100
Study 35940353 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 100
Study 35940353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone group
Number of subjects: 100
Study 35940353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 34256830 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (smartphone app with personalized program of resistance, balance, and daily activity training exercises)
Number of subjects: 230
Study 34256830 — intervention group
Group type: COMPARATOR
Intervention: Control (usual flow of public healthcare system)
Number of subjects: 230
Study 35124335 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed chest compression technique (OHCC)
Number of subjects: 32
Study 35124335 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed chest compression technique (THCC)
Number of subjects: 32
Study 36435545 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion exercise
Number of subjects: 24
Study 36435545 — intervention group
Group type: COMPARATOR
Intervention: Neutral exercise
Number of subjects: 24
Study 33992290 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tardieu Scale (MTS) for assessing knee extensor spasticity
Number of subjects: 26
Study 32974907 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg racemic VEN
Number of subjects: 10
Study 32974907 — intervention group
Group type: COMPARATOR
Intervention: 40 mg nifedipine with VEN
Number of subjects: 10
Study 33332157 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit intervention using the SHAPE CODING system, once‐weekly sessions over 10 weeks
Number of subjects: 21
Study 33332157 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no intervention during the first phase)
Number of subjects: 21
Study 33332157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received the intervention after crossover
Number of subjects: 21
Study 33332157 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures of grammar
Number of subjects: 21
Study 33332157 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension and control measures of morphosyntax
Number of subjects: 21
Study 35549744 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research contributions to trial design and conduct
Number of subjects: 0
Study 35549744 — intervention group
Group type: EXPERIMENTAL
Intervention: One research team approach
Number of subjects: 0
Study 35549744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained and sufficient funding for qualitative research
Number of subjects: 0
Study 35549744 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared infrastructure and resources
Number of subjects: 0
Study 35549744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual recognition of different methods and perspectives
Number of subjects: 0
Study 32146876 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 157
Study 32146876 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Body-Mind-Spirit Intervention (I‐BMS)
Number of subjects: 157
Study 32146876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 157
Study 35810307 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg (Group A)
Number of subjects: 900
Study 35810307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg (Group B)
Number of subjects: 900
Study 35810307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Atorvastatin and Aspirin (Group C)
Number of subjects: 900
Study 35810307 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (Group D)
Number of subjects: 900
Study 35810307 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin vs Control (Group D)
Number of subjects: 900
Study 35810307 — intervention group
Group type: COMPARATOR
Intervention: Aspirin vs Control (Group D)
Number of subjects: 900
Study 35810307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (Group B)
Number of subjects: 900
Study 33682997 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% bovine milk fat and 33% vegetable fat (BOV)
Number of subjects: 20
Study 33682997 — intervention group
Group type: COMPARATOR
Intervention: 100% vegetable fat (VEG)
Number of subjects: 20
Study 33865929 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIT-ED treatment (n = 64)
Number of subjects: 114
Study 33865929 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (n = 50)
Number of subjects: 114
Study 34098039 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report adherence at 3 weeks
Number of subjects: 332
Study 34098039 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report adherence at 7 weeks
Number of subjects: 332
Study 34098039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill counts adherence at 3 weeks
Number of subjects: 332
Study 34098039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill counts adherence at 7 weeks
Number of subjects: 332
Study 34098039 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between self-report and pill counts at 3 weeks
Number of subjects: 332
Study 34098039 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between self-report and pill counts at 7 weeks
Number of subjects: 332
Study 35893890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week Few-Foods Diet (FFD)
Number of subjects: 0
Study 35893890 — intervention group
Group type: COMPARATOR
Intervention: Healthy food advice (Control)
Number of subjects: 0
Study 33600874 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n = 75)
Number of subjects: 144
Study 33600874 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 69)
Number of subjects: 144
Study 34538193 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimanual mirror therapy (UMT)
Number of subjects: 22
Study 34538193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual mirror therapy (BMT)
Number of subjects: 22
Study 34538193 — intervention group
Group type: COMPARATOR
Intervention: Traditional occupational therapy (TOT)
Number of subjects: 22
Study 32459129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (800 mg)
Number of subjects: 17
Study 32459129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 35385098 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 35385098 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 33269670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexed semen (INR 340 per straw)
Number of subjects: 210
Study 33269670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexed semen (INR 770 per straw)
Number of subjects: 210
Study 33342939 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 250
Study 33342939 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 250
Study 33853806 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 288
Study 33853806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 36170242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan procedure group
Number of subjects: 40
Study 36170242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33737438 — intervention group
Group type: EXPERIMENTAL
Intervention: High burden of depression symptoms (BDI score ≥13 or CES-D score ≥10)
Number of subjects: 1464